Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Nabi Biopharmaceuticals

Home Clinical Trial Sponsors and OrganizationsNabi Biopharmaceuticals

Nabi Biopharmaceuticals

CLOSED

1130 Garden Way, 马里兰州蒙哥马利县, 马里兰州, United Stateswww.nabi.comPrivate1–10 employeesEstablished: 1967-01-01

Part of Aviragen Therapeutics, Inc.

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

18

0 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

1967

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 3

12

66.7%

Phase 1

2

11.1%

Phase 2

2

11.1%

Phase 4

1

5.6%

Trial Status Distribution

Completed

17

94.4%

Terminated

1

5.6%

Clinical Trials

Trials sponsored by this organization (18)

A Comparability Study of the Phase 3 Lot and a Single Commercial Lot of NicVAX in Healthy Adult Smokers

May 2011260 participants

A Follow-up Study to Assess Long-term Immunogenicity and Safety of NicVAX/Placebo as an Aid to Smoking Cessation

Jan 2011300 participants

Pharmacoeconomic Assessment in Nabi-4514 and Nabi-4515 Phase 3 Studies

Jul 2010500 participants

A Second Study of NicVAX/Placebo as an Aid for Smoking Cessation

Mar 20101,000 participants

NicVAX/Placebo as an Aid for Smoking Cessation

Oct 20091,000 participants

Antibody and Safety Study of 6 Doses of NicVAX in Smokers

Jan 200874 participants

Evaluation of a Third and Fourth Dose of StaphVAX® in Adults With End-Stage Renal Disease

Aug 200599 participants

EPIC(Effect of PhosLo on Phosphorus Levels in Chronic Kidney Disease)

May 2005110 participants

Page 1 of 3

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials18
Approvals
News

Back to Organizations